Toleranzia AB (TOL.ST)

SEK 0.41

(-0.24%)

Total Liabilities Summary of Toleranzia AB

Toleranzia AB's latest annual total liabilities in 2023 was 6.9 Million SEK , up 12.84% from previous year.
Toleranzia AB's latest quarterly total liabilities in 2024 Q1 was 3.86 Million SEK , down -44.02% from previous quarter.
Toleranzia AB reported annual total liabilities of 6.12 Million SEK in 2022, up 43.59% from previous year.
Toleranzia AB reported annual total liabilities of 4.26 Million SEK in 2021, down -8.33% from previous year.
Toleranzia AB reported quarterly total liabilities of 18.15 Million SEK for 2024 Q3, up 247.47% from previous quarter.
Toleranzia AB reported quarterly total liabilities of 5.22 Million SEK for 2024 Q2, up 35.11% from previous quarter.

Annual Total Liabilities Chart of Toleranzia AB (2023 - 2012)

Historical Annual Total Liabilities of Toleranzia AB (2023 - 2012)

Year	Total Liabilities	Total Liabilities Growth
2023	6.9 Million SEK	12.84%
2022	6.12 Million SEK	43.59%
2021	4.26 Million SEK	-8.33%
2020	4.65 Million SEK	26.95%
2019	3.66 Million SEK	30.76%
2018	2.8 Million SEK	33.09%
2017	2.1 Million SEK	-5.39%
2016	2.22 Million SEK	-20.67%
2015	2.8 Million SEK	97.9%
2014	1.41 Million SEK	48.89%
2013	952.24 Thousand SEK	-47.33%
2012	1.8 Million SEK	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	3.86 Million SEK	-44.02%
2024 Q3	18.15 Million SEK	247.47%
2024 Q2	5.22 Million SEK	35.11%
2023 Q2	6.9 Million SEK	24.95%
2023 Q1	5.52 Million SEK	-9.82%
2023 FY	6.9 Million SEK	12.84%
2023 Q4	6.9 Million SEK	-18.26%
2023 Q3	8.45 Million SEK	22.49%
2022 Q3	4.41 Million SEK	-15.2%
2022 FY	6.12 Million SEK	43.59%
2022 Q4	6.12 Million SEK	38.75%
2022 Q1	5.64 Million SEK	32.33%
2022 Q2	5.2 Million SEK	-7.78%
2021 Q1	4.96 Million SEK	6.67%
2021 Q4	4.26 Million SEK	-39.54%
2021 Q3	7.05 Million SEK	22.45%
2021 FY	4.26 Million SEK	-8.33%
2021 Q2	5.76 Million SEK	16.08%
2020 Q1	3.24 Million SEK	-11.4%
2020 Q2	3.57 Million SEK	10.05%
2020 Q3	3.29 Million SEK	-7.76%
2020 Q4	4.65 Million SEK	41.15%
2020 FY	4.65 Million SEK	26.95%
2019 Q2	2.21 Million SEK	-11.91%
2019 Q1	2.52 Million SEK	-10.08%
2019 Q4	3.66 Million SEK	42.57%
2019 Q3	2.57 Million SEK	15.79%
2019 FY	3.66 Million SEK	30.76%
2018 Q2	2.12 Million SEK	-53.61%
2018 Q4	2.8 Million SEK	35.44%
2018 FY	2.8 Million SEK	33.09%
2018 Q3	2.06 Million SEK	-2.52%
2018 Q1	4.57 Million SEK	117.28%
2017 Q1	1.85 Million SEK	-16.82%
2017 FY	2.1 Million SEK	-5.39%
2017 Q2	2.12 Million SEK	14.89%
2017 Q4	2.1 Million SEK	12.88%
2017 Q3	1.86 Million SEK	-12.3%
2016 Q1	2.69 Million SEK	-4.09%
2016 FY	2.22 Million SEK	-20.67%
2016 Q3	2.35 Million SEK	-5.78%
2016 Q2	2.5 Million SEK	-6.99%
2016 Q4	2.22 Million SEK	-5.62%
2015 Q1	- SEK	-100.0%
2015 FY	2.8 Million SEK	97.9%
2015 Q4	2.8 Million SEK	0.0%
2014 FY	1.41 Million SEK	48.89%
2014 Q4	1.41 Million SEK	0.0%
2013 FY	952.24 Thousand SEK	-47.33%
2012 FY	1.8 Million SEK	0.0%

Peer Total Liabilities Comparison of Toleranzia AB

Name	Total Liabilities	Total Liabilities Difference
AcuCort AB	10.97 Million SEK	37.048%
AlzeCure Pharma AB (publ)	8.22 Million SEK	16.02%
BioGaia AB (publ)	302.84 Million SEK	97.719%
Enzymatica AB (publ)	49.3 Million SEK	85.986%
Enorama Pharma AB (publ)	14.84 Million SEK	53.465%
Gabather AB (publ)	6.87 Million SEK	-0.451%
Klaria Pharma Holding AB (publ.)	31.98 Million SEK	78.4%
Moberg Pharma AB (publ)	24 Million SEK	71.221%
Nanexa AB (publ)	36.42 Million SEK	81.033%
Newbury Pharmaceuticals AB (publ)	38.95 Million SEK	82.264%
ODI Pharma AB	10.05 Million SEK	31.306%
Orexo AB (publ)	727.7 Million SEK	99.051%
Probi AB (publ)	181.31 Million SEK	96.19%
Swedencare AB (publ)	2.31 Billion SEK	99.702%
Swedish Orphan Biovitrum AB (publ)	40.16 Billion SEK	99.983%
Vivesto AB	30.45 Million SEK	77.312%